Daraxonrasib extends survival in metastatic pancreatic cancer
1. Daraxonrasib is the first-in-class RAS inhibitor approved for metastatic pancreatic adenocarcinoma, addressing a molecular pathway that drives most pancreatic ...
1. Daraxonrasib is the first-in-class RAS inhibitor approved for metastatic pancreatic adenocarcinoma, addressing a molecular pathway that drives most pancreatic ...
1. Exposure to systemic glucocorticoid immunosuppression (gsISP) close to immune checkpoint inhibitor (ICI) initiation was associated with worse overall survival ...
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Click here to read this study in Nature Medicine. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
1. In this cohort study, physical activity was associated with improved disease-free survival in postoperative stage III colon cancer patients ...
1. In this phase 3 nonrandomized controlled trial, among 331 patients, patients with newly diagnosed glioblastoma (nGBM) receiving dendritic cell ...
This study summary is an excerpt from the book 2 Minute Medicine's The Classics in Medicine: Summaries of the Landmark ...
This study summary is an excerpt from the book 2 Minute Medicine's The Classics in Medicine: Summaries of the Landmark ...
1. Patients receiving pembrolizumab with or without platinum-based chemotherapy experienced longer progression-free and overall survival than the placebo group. 2. ...
5-day free trial · cancel anytime
Then $4.99/month. Manage renewal in your account.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
Monthly plan selected: $4.99 /month.
5-day free trial · cancel anytime
Then $4.99/month. Manage renewal in your account.
Yearly plan selected: $49.90 /year.
2 months free · only $4.16/month
Then $49.90/year. Manage renewal in your account.
Already a member? Sign in